Vect-Horus Overview
- Founded
-
2005

- Status
-
Private
- Employees
-
36

- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1M
- Investors
-
7
Vect-Horus General Information
Description
Developer of a targeted drug delivery system intended to enhance the transport of biotherapeutics across biological barriers. The company's system is based on the specific design and optimization of molecular vectors that once conjugated to a payload delivered to target cells in the body, enabling healthcare providers to improve therapeutic or diagnostic benefits while minimizing both dose levels and off-target effects of newly developed molecules.
Contact Information
Website
www.vect-horus.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Drug Discovery
Primary Office
- Faculté de la Timone
- 27 Boulevard Jean Moulin 1er étage aile Verte
- 13005 Marseille
- France
+33 04 00 00 00 00
Vect-Horus Timeline
Vect-Horus Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
10. Grant | 01-Feb-2022 | $1M | 000.00 | Completed | Generating Revenue | |
9. Later Stage VC (Series D) | 01-Dec-2020 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
8. Later Stage VC | 07-Jun-2018 | 00.000 | 000.00 | 0000 | Completed | Generating Revenue |
7. Later Stage VC | 21-Mar-2017 | 00.000 | 000.00 | 0000 | Completed | Generating Revenue |
6. Accelerator/Incubator | 00.000 | Completed | Generating Revenue | |||
5. Angel (individual) | 00.000 | 00.000 | Completed | Generating Revenue | ||
4. Later Stage VC | 15-Dec-2014 | 00.000 | 00.000 | Completed | Generating Revenue | |
3. Grant | 00.000 | Completed | Startup | |||
2. Later Stage VC | 28-May-2013 | Completed | Startup | |||
1. Later Stage VC | 28-May-2011 | Completed | Startup |
Vect-Horus Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | 000,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
Ordinary | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
Vect-Horus Patents
Vect-Horus Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020206593-A1 | Transferrin receptor-binding molecules, conjugates thereof and their uses | Pending | 09-Jan-2019 | 00000000000 | |
EP-3908608-A1 | Transferrin receptor-binding molecules, conjugates thereof and their uses | Pending | 09-Jan-2019 | 00000000000 | |
JP-2022518392-A | Transferrin receptor binding molecule, its conjugate, and its use | Pending | 09-Jan-2019 | 00000000000 | |
CA-3124790-A1 | Transferrin receptor-binding molecules, conjugates thereof and their uses | Pending | 09-Jan-2019 | 00000000000 | |
US-20220090050-A1 | Transferrin receptor-binding molecules, conjugates thereof and their uses | Pending | 09-Jan-2019 | C12N15/1037 |
Vect-Horus Executive Team (3)
Vect-Horus Board Members (1)
Name | Representing | Role | Since |
---|---|---|---|
Alexandre Tokay | Vect-Horus | Co-Founder, Chief Executive Officer, & Chairman | 000 0000 |
Vect-Horus Signals
Vect-Horus Investors (7)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
European Union | Government | 000 0000 | 000000 0 | ||
Bpifrance | Sovereign Wealth Fund | Minority | 000 0000 | 000000 0 | |
CAAP Creation | Venture Capital | Minority | 000 0000 | 000000 0 | |
Financiere Tuileries | Corporation | Minority | 000 0000 | 000000 0 | |
Alizee Investment | Corporation | Minority | 000 0000 | 000000 0 |